Ardelyx Inc Revenue Growth Rates (ARDX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Ardelyx inc   (NASDAQ: ARDX)
 

ARDX's Revenue Growth by Quarter and Year

Ardelyx Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ARDX/growth
https://api.csimarket.com/api/v1/companies/ARDX/fundamentals
https://api.csimarket.com/api/v1/companies/ARDX/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
ARDX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 127.66
2nd Quarter June 120.88
1st Quarter March 94.47
FY 343.01

ARDXs Annual Revenue
Ardelyx Inc 's Revenue in the fiscal year 2025 $ 407.32 millions
Ardelyx Inc 's Revenue in the fiscal year 2024 $ 333.62 millions
Ardelyx Inc 's Revenue in the fiscal year 2023 $ 124.46 millions
Ardelyx Inc 's Revenue in the fiscal year 2022 $ 52.16 millions
Ardelyx Inc 's Revenue in the fiscal year 2021 $ 10.10 millions




ARDX Revenue third quarter 2026 Y/Y Growth Comment
Ardelyx inc reported Revenue increase of 15.7% year on year in the third quarter 2026, to $ 127.66 millions, this is lower than Ardelyx Inc 's recent average Revenue surge of 655.79%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 78 other companies have achieved higher Revenue growth. While Ardelyx Inc ' s Revenue growth of 15.7% ranks overall at the positon no. 897 in the third quarter 2026.


ARDX Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 15.7 %
2nd Quarter June 23.78 %
1st Quarter March 27.47 %
FY   -

Financial Statements
Ardelyx Inc 's third quarter 2026 Revenue $ 127.66 millions ARDX's Income Statement
Ardelyx Inc 's third quarter 2025 Revenue $ 110.33 millions Quarterly ARDX's Income Statement


ARDX Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 5.6 %
2nd Quarter June 27.96 %
1st Quarter March -24.56 %
FY (Year on Year)   -


Back to ARDX Growth rate Comparisons >> Back to ARDX Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #79
Healthcare Sector #184
Overall #897

Revenue Y/Y Growth Statistics
High Average Low
10100 % 655.79 % -100 %
(Jun 30 2023)   (Mar 31 2022)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #79
Healthcare Sector #184
Overall #897
Revenue Y/Y Growth Statistics
High Average Low
10100 % 655.79 % -100 %
(Jun 30 2023)   (Mar 31 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Ardelyx Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
16638.89 % 422.65 % -100 %
(Sep 30 2019)  


ARDX's III. Quarter Q/Q Revenue Comment
Ardelyx inc achieved in the III. Quarter 2026 below company average Revenue increase of 5.6% quarter on quarter, to $ 127.66 millions.

Within Major Pharmaceutical Preparations industry 41 other companies have achieved higher Revenue quarter on quarter growth. While Ardelyx Inc 's Revenue growth quarter on quarter, overall rank is 386.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #42
Healthcare Sector #85
Overall #386
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #42
Healthcare Sector #85
Overall #386
Revenue Q/Q Growth Statistics
High Average Low
16638.89 % 422.65 % -100 %
(Sep 30 2019)  


ARDX's III. Quarter Q/Q Revenue Comment
Ardelyx inc achieved in the III. Quarter 2026 below company average Revenue increase of 5.6% quarter on quarter, to $ 127.66 millions.

Within Major Pharmaceutical Preparations industry 41 other companies have achieved higher Revenue quarter on quarter growth. While Ardelyx Inc 's Revenue growth quarter on quarter, overall rank is 386.


Ardelyx Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 468.22
Y / Y Revenue Growth (TTM) 17.57 %
Year on Year Revenue Growth Overall Ranking # 198
Seqeuential Revenue Change (TTM) 3.84 %
Seq. Revenue Growth (TTM) Overall Ranking # 1878


Cumulative Revenue growth Comment
Although Ardelyx Inc 's Annual Revenue growth year on year were below company's average 341.27% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 17.57% year on year, from 16.77% in Jun 30 2026.

In the Healthcare sector 52 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 115 to 198.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 98
Healthcare Sector # 53
Overall # 198

Revenue TTM Y/Y Growth Statistics
High Average Low
2564.1 %
 341.27 %
-92.92 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 98
Sector # 292
S&P 500 # 1878
Cumulative Revenue growth Comment
Although Ardelyx Inc 's Annual Revenue growth year on year were below company's average 341.27% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 17.57% year on year, from 16.77% in Jun 30 2026.

In the Healthcare sector 52 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 115 to 198.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 98
Healthcare Sector # 53
Overall # 198

Revenue TTM Y/Y Growth Statistics
High Average Low
2564.1 %
341.27 %
-92.92 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 98
Sector # 292
S&P 500 # 1878




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ARDX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Geron Corporation27.45%$ 27.448 millions
Vericel Corporation26.47%$ 26.470 millions
Axogen inc 26.22%$ 26.218 millions
Cardio Diagnostics Holdings Inc 25.74%$ 25.744 millions
Edap Tms Sa25.55%$ 25.549 millions
Lifestance Health Group Inc 25.30%$ 25.303 millions
Rockwell Medical inc 25.21%$ 25.210 millions
Intelligent Bio Solutions Inc 25.19%$ 25.188 millions
The Oncology Institute Inc 24.31%$ 24.313 millions
Vanda Pharmaceuticals Inc 24.10%$ 24.098 millions
Mannkind Corporation24.04%$ 24.035 millions
Castle Biosciences Inc 23.90%$ 23.901 millions
Coherus Oncology inc 23.36%$ 23.360 millions
Prestige Consumer Healthcare Inc 22.93%$ 22.929 millions
Acadia Pharmaceuticals Inc 22.85%$ 22.847 millions
Protalix Biotherapeutics inc 22.82%$ 22.822 millions
Atrium Therapeutics Inc 22.81%$ 22.814 millions
Capsovision Inc 22.44%$ 22.443 millions
Veracyte Inc 22.10%$ 22.105 millions
Radnet Inc 22.07%$ 22.068 millions
Alkermes Plc 21.80%$ 21.804 millions
Alpha Teknova Inc 21.52%$ 21.523 millions
Anteris Technologies Global Corp 20.98%$ 20.979 millions
Trisalus Life Sciences Inc 20.81%$ 20.807 millions
Orthopediatrics Corp20.55%$ 20.551 millions
Alpha Pro Tech Ltd 19.73%$ 19.729 millions
Insulet Corporation19.21%$ 19.213 millions
Abcellera Biologics Inc 18.81%$ 18.805 millions
Schrodinger Inc 18.72%$ 18.715 millions
Procept Biorobotics Corporation18.41%$ 18.414 millions


About Ardelyx Inc Revenue Growth Rates (ARDX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Ardelyx Inc (CIK 1437402).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001437402-26-000059
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Ardelyx Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.